Seroprevalence of antibodies against human papillomavirus (HPV) types 16 and 18 in four continents: The International Agency for Research on Cancer HPV prevalence surveys

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 9, 2010, Pages 2379-2388

  Vaccarella, Salvatore ^a   Franceschi, Silvia ^a   Clifford, Gary M ^a   Touzé, Antoine ^b   Hsu, Charles C ^c   De Sanjosé, Silvia ^d,e   Anh, Pham Thi Hoang ^f   Hieu, Nguyen Trong ^g   Matos, Elena ^h   Shin, Hai Rim ^a,i   Sukvirach, Sukhon ^j   Thomas, Jaiye O ^k   Boursaghin, Latifa ^b,o   Gaitan, Julien ^b   Snijders, Peter J F ^l   Meijer, Chris J L M ^l   Muñoz, Nubia ^m   Herrero, Rolando ⁿ   Coursaget, Pierre ^b  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^e CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^f National Cancer Institute   (Viet Nam)

^g Hung Vuong Hospital   (Viet Nam)

^h UNIVERSIDAD DE BUENOS AIRES   (Argentina)

ⁱ National Cancer Center   (South Korea)

^j NATIONAL CANCER INSTITUTE   (Thailand)

^k UNIVERSITY OF IBADAN   (Nigeria)

^l VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^m Instituto Nacional de Cancerología   (Colombia)

ⁿ PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^o Institute de Chimie de'Rennes   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; VIRUS DNA;

ADULT; ANTIBODY BLOOD LEVEL; ARGENTINA; ARTICLE; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; KOREA; MAJOR CLINICAL STUDY; NIGERIA; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RESEARCH; SEROLOGY; SEROPREVALENCE; SEXUAL BEHAVIOR; SPAIN; THAILAND; VIET NAM;

ADULT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; SEROEPIDEMIOLOGIC STUDIES; WORLD HEALTH;

EID: 77956507911     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0336     Document Type: Article

References (49)

1. IARC. Monographs on the evaluation of carcinogenic risks to humans. Volume 90: human papillomaviruses. Lyon: IARC; 2007.
2. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. Epub 2010 Apr 19.
3. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8. (Pubitemid 28135669)
4. Shah KV, Viscidi RP, Alberg AJ, Helzlsouer KJ, Comstock GW. Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. Cancer Epidemiol Biomarkers Prev 1997;6: 233-7.
5. Clifford GM, Shin HR, Oh JK, et al. Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev 2007;16: 1874-9.
6. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911-9.
7. Combita AL, Bravo MM, Touzé A, Orozco O, Coursaget P. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in Colombian women with invasive cervical cancer. Int J Cancer 2002;97:796-803.
8. Ho GY, Studentsov YY, Bierman R, Burk RD. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004;13:110-6. (Pubitemid 38116628)
9. Jit M, Vyse A, Borrow R, Pebody R, Soldan K, Miller E. Prevalence of human papillomavirus antibodies in young female subjects in England. Br J Cancer 2007;97:989-91. (Pubitemid 47519301)
10. Lehtinen M, Pawlita M, Zumbach K, et al. Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later. Am J Obstet Gynecol 2003;188:49-55. (Pubitemid 36135597)
11. Michael KM, Waterboer T, Sehr P, et al. Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog 2008;4:e1000091.
12. Newall AT, Brotherton JM, Quinn HE, et al. Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clin Infect Dis 2008;46:1647-55.
13. Skjeldestad FE, Mehta V, Sings HL, et al. Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics. Acta Obstet Gynecol Scand 2008;87:81-8.
14. Stone KM, Karem KL, Sternberg MR, et al. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 2002;186:1396-402.
15. Rama CH, Roteli-Martins CM, Derchain SF, Oliveira EZ, Aldrighi JM, Mariani NC. [Serological detection of anti HPV 16/18 and its association with pap smear in adolescents and young women]. Rev Assoc Med Bras 2006;52:43-7.
16. Viscidi RP, Schiffman M, Hildesheim A, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004;13:324-7.
17. Wang SS, Schiffman M, Shields TS, et al. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer 2003;89:1248-54. (Pubitemid 37363412)
18. Wang IJ, Viscidi R, Hwang KC, et al. Seroprevalence and risk factors for human papillomavirus in Taiwan. J Trop Pediatr 2008;54:14-8. (Pubitemid 351234404)
19. Newton R, Bousarghin L, Ziegler J, et al. Human papillomaviruses and cancer in Uganda. Eur J Cancer Prev 2004;13:113-8.
20. Franceschi S, Herrero R, Clifford GM, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006;119:2677-84.
21. de Sanjosé S, Almirall R, Lloveras B, et al. Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis 2003;30:788-93. (Pubitemid 37229490)
22. Matos E, Loria D, Amestoy G, et al. Prevalence of human papillomavirus infection among women in Concordia, Argentina: a population-based study. Sex Transm Dis 2003;30:593-9.
23. Shin HR, Lee DH, Herrero R, et al. Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer 2003; 103:413-21. (Pubitemid 36076436)
24. Sukvirach S, Smith JS, Tunsakul S, et al. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis 2003;187:1246-56. (Pubitemid 36438965)
25. Anh PT, Hieu NT, Herrero R, et al. Human papillomavirus infection among women in South and North Vietnam. Int J Cancer 2003; 104:213-20. (Pubitemid 36249797)
26. Thomas JO, Herrero R, Omigbodun AA, et al. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer 2004;90:638-45. (Pubitemid 38297204)
27. Combita AL, Touzé A, Bousarghin L, Christensen ND, Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 2002;76: 6480-6. (Pubitemid 34633513)
28. Touzé A, de Sanjosé S, Coursaget P, et al. Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes. J Clin Microbiol 2001;39: 4344-8.
29. Bayo S, Bosch FX, de Sanjosé S, et al. Risk factors of invasive cervical cancer in Mali. Int J Epidemiol 2002;31:202-9. (Pubitemid 34284928)
30. Jacobs MV, Walboomers JM, Snijders PJ, et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 2000;87:221-7.
31. Jacobs MV, Roda Husman AM, van den Brule AJ, Snijders PJ, Meijer CJ, Walboomers JM. Group-specific differentiation between high-and low-risk human papillomavirus genotypes by general primermediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol 1995;33:901-5.
32. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002;40:779-87.
33. Ribes JA, Hayes M, Smith A, Winters JL, Baker DJ. Comparative performance of herpes simplex virus type 2-specific serologic assays from Meridian Diagnostics and MRL diagnostics. J Clin Microbiol 2001;39:3740-2.
34. Studentsov YY, Ho GY, Marks MA, Bierman R, Burk RD. Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses. J Clin Microbiol 2003;41: 2827-34.
35. Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirusinfected women. J Natl Cancer Inst 2002;94:1406-14.
36. Dillner J, Kallings I, Brihmer C, et al. Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 1996;173:1394-8.
37. Kreimer AR, Alberg AJ, Viscidi R, Gillison ML. Gender differences in sexual biomarkers and behaviors associated with human papillomavirus- 16, -18, and -33 seroprevalence. Sex Transm Dis 2004;31: 247-56.
38. Strickler HD, Kirk GD, Figueroa JP, et al. HPV 16 antibody prevalence in Jamaica and the United States reflects differences in cervical cancer rates. Int J Cancer 1999;80:339-44.
39. Svare EI, Kjaer SK, Nonnenmacher B, et al. Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk women. J Infect Dis 1997;176:876-83.
40. Wang ZH, Kjellberg L, Abdalla H, et al. Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids. J Infect Dis 2000;181:456-62. (Pubitemid 30131810)
41. Vaccarella S, Franceschi S, Herrero R, et al. Sexual behavior, condom use and HPV: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev 2006;15:326-33.
42. Vaccarella S, Herrero R, Snijders PJ, et al. Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol 2008; 37:536-46. (Pubitemid 351804006)
43. Tachezy R, Hamsikova E, Hajek T, et al. Human papillomavirus genotype spectrum in Czech women: correlation of HPV DNA presence with antibodies against HPV-16, 18, and 33 virus-like particles. J Med Virol 1999;58:378-86. (Pubitemid 29326052)
44. de Sanjosé S, Hamsikova E, Muñoz N, et al. Serological response to HPV16 in CIN-III and cervical cancer patients. Case-control studies in Spain and Colombia. Int J Cancer 1996;66:70-4.
45. Dillner J, Lehtinen M, Bjorge T, et al. Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst 1997;89:1293-9. (Pubitemid 27371950)
46. Naucler P, Chen HC, Persson K, et al. Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested case-control study. J Gen Virol 2007;88:814-22. (Pubitemid 46359550)
47. Sigstad E, Lie AK, Luostarinen T, et al. A prospective study of the relationship between prediagnostic human papillomavirus seropositivity and HPV DNA in subsequent cervical carcinomas. Br J Cancer 2002;87:175-80.
48. Wang SS, Schiffman M, Herrero R, et al. Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica. Br J Cancer 2004;91:1269-74. Available from: http://www.ncbi.nlm.nih.gov/ sites//pubmed/15292929.
49. Pagliusi SR, Dillner J, Pawlita M, Quint WG, Wheeler CM, Ferguson M. Chapter 23: International Standard reagents for harmonization of HPV serology and DNA assays - an update. Vaccine 2006;24 Suppl 3:S3/193-S3/200.